Patients with underdiagnosed and untreated viral hepatitis infections can develop chronic and even fatal conditions that impact quality of life and cost of care.
Viral hepatitis infections are frequently associated with mild symptoms or may be entirely asymptomatic. If untreated, viral hepatitis infections can cause hardening and scarring cirrhosis of the liver. Access to regular screening can prevent further spread of infections and progression of disease to avoid unnecessary health complications.
Roche’s commitment to hepatology is well-established, with awareness programs in partnership with NGOs and government organizations, as well as high-quality diagnostic solutions that address the patient needs. We offer well-designed assays and fully automated systems to screen and diagnose disease or monitor viral load. Improving access to testing can help to limit the financial burden of viral hepatitis at the country level while reducing the impact on quality of life for patients.
